Cargando…

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial

BACKGROUND: Booster vaccination is an efficient way to address the waning protection of vaccines and immune escape of SARS-CoV-2 variants. We aimed to assess the safety and immunogenicity of SCTV01C, a novel bivalent protein vaccine as a booster for people who previously received two doses of mRNA v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hannawi, Suad, Saifeldin, Linda, Abuquta, Alaa, Alamadi, Ahmad, Mahmoud, Sally A., Hassan, Aala, Liu, Dongfang, Yan, Lixin, Xie, Liangzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720098/ https://www.ncbi.nlm.nih.gov/pubmed/36470077 http://dx.doi.org/10.1016/j.ebiom.2022.104386

Ejemplares similares

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022)

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
por: Hannawi, Suad, et al.
Publicado: (2023)

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial
por: Hannawi, Suad, et al.
Publicado: (2023)

Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial
por: Wang, Guiqiang, et al.
Publicado: (2022)

A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models
por: Sun, Chunyun, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study
por: Hannawi, Suad, et al.
Publicado: (2023)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
por: Tan, Ngoc H., et al.
Publicado: (2022)

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19
por: Gupta, Sneh Lata, et al.
Publicado: (2022)

Axillary lymphadenopathy following bivalent COVID-19 booster vaccination
por: Lane, Elizabeth G., et al.
Publicado: (2023)

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination
por: Saxena, Divyasha, et al.
Publicado: (2023)

Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination
por: Terbsiri, Varalee, et al.
Publicado: (2023)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Immunogenicity of Individual Vaccine Components in a Bivalent Nicotine Vaccine Differ According to Vaccine Formulation and Administration Conditions
por: Cornish, Katherine E., et al.
Publicado: (2013)

Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine
por: Turner, Hugo C., et al.
Publicado: (2013)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
por: Alcendor, Donald J., et al.
Publicado: (2023)

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
por: Chalkias, Spyros, et al.
Publicado: (2022)

COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022
por: Lu, Peng-jun, et al.
Publicado: (2023)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle
por: Moreira, Clóvis, et al.
Publicado: (2018)

Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
por: Anft, Moritz, et al.
Publicado: (2023)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

Immunogenicity of a Bivalent Adjuvanted Glycoconjugate Vaccine against Salmonella Typhimurium and Salmonella Enteritidis
por: Fiorino, Fabio, et al.
Publicado: (2017)

Trial Evaluation of Protection and Immunogenicity of Piscine Bivalent Streptococcal Vaccine: From the Lab to the Farms
por: Kannika, Korntip, et al.
Publicado: (2022)

Serological Responses in Cattle following Booster Vaccination against Serotypes 4 and 8 Bluetongue Virus with Two Bivalent Commercial Inactivated Vaccines
por: Sailleau, Corinne, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
por: Sablerolles, Roos S.G., et al.
Publicado: (2022)

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations
por: Stoliaroff-Pepin, Anna, et al.
Publicado: (2023)

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
por: Chalkias, Spyros, et al.
Publicado: (2023)

Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination
por: Fitzpatrick, Meagan C., et al.
Publicado: (2023)

EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom
por: Kohli, M., et al.
Publicado: (2023)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model
por: Lee, Eun Young, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h8g4sl79qi3i6jhq09l64kprig